Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -34.4% |
| R&D Expenses | $2 | $4 | $2 | $3 |
| G&A Expenses | $7 | $5 | $5 | $8 |
| SG&A Expenses | $7 | $5 | $5 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $3 | $3 | $0 |
| Operating Expenses | $9 | $11 | $10 | $11 |
| Operating Income | -$9 | -$11 | -$10 | -$11 |
| % Margin | – | – | – | -7,087% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$9 | -$11 | -$10 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$11 | -$10 | -$11 |
| % Margin | – | – | – | -6,920.1% |
| EPS | -0.8 | -1.27 | -1.3 | -1.59 |
| % Growth | 37% | 2.3% | 18.2% | – |
| EPS Diluted | -0.8 | -1.27 | -1.3 | -1.7 |
| Weighted Avg Shares Out | 11 | 12 | 12 | 12 |
| Weighted Avg Shares Out Dil | 11 | 12 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$11 | -$10 | -$11 |
| % Margin | – | – | – | -7,052.6% |